Since August 7th, treatment with neuraminidase inhibitors (oseltamivir) in the Netherlands has been limited to those patient groups who are considered at high risk of influenza-related complications. This policy is based on one study which shows only limited evidence of the effectiveness of neuraminidase inhibitors in lowering the number of such complications.